[HTML][HTML] Immunotherapeutic approaches targeting amyloid-β, α-synuclein, and tau for the treatment of neurodegenerative disorders
E Valera, B Spencer, E Masliah - Neurotherapeutics, 2016 - Elsevier
Disease-modifying alternatives are sorely needed for the treatment of neurodegenerative
disorders, a group of diseases that afflict approximately 50 million Americans annually.
Immunotherapy is one of the most developed approaches in this direction. Vaccination
against amyloid-β, α-synuclein, or tau has been extensively explored, specially as the
discovery that these proteins may propagate cell-to-cell and be accessible to antibodies
when embedded into the plasma membrane or in the extracellular space. Likewise, the use …
disorders, a group of diseases that afflict approximately 50 million Americans annually.
Immunotherapy is one of the most developed approaches in this direction. Vaccination
against amyloid-β, α-synuclein, or tau has been extensively explored, specially as the
discovery that these proteins may propagate cell-to-cell and be accessible to antibodies
when embedded into the plasma membrane or in the extracellular space. Likewise, the use …
